Baxter reports new data on Advate therapy benefits

Baxter has presented new clinical information on its drug Advate that shed light on how it can be used to offer maximum benefit to haemophilia patients.

New findings from a post-hoc analysis of an Advate prophylaxis study showed a correlation between peak levels of factor VIII in the body and the efficacy of treatment, suggesting that the frequency of peaks may be important when choosing haemophilia treatments.

Meanwhile, a second study revealed that low annual bleed rates are the most critical goal for people living with haemophilia, with patients and carers alike considering this more important than infusion convenience.

Dr Anders Ullman, vice-president of global research and development at Baxter's bioscience division, said: "Meeting the needs of individual patients and raising the standard of care are the primary focus of Baxter's long-term commitment in haemophilia."

These findings were presented at the International Society on Thrombosis and Haemostasis annual congress, which took place in Amsterdam earlier this week.

During the meeting, Baxter also reported data showcasing the strong performance of Advate in both real-world and clinical settings.